The EUropean TRAnsplantation and INnovation EU TRAIN consortium for improving...
The EUropean TRAnsplantation and INnovation EU TRAIN consortium for improving diagnosis and risk stratification in kidney transplant patients
Rejection is the major cause of allograft failure with dramatic consequences in terms of mortality, morbidity and increased cost for the society. The field of transplantation lacks a robust assessment of risk stratification. Thus,...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
TRANSBIO
A BIOmarker based assay for prognosis and monitoring in rena...
71K€
Cerrado
AI CARE
Integrated AI-Driven Systems For Kidney Transplant Precision...
2M€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Rejection is the major cause of allograft failure with dramatic consequences in terms of mortality, morbidity and increased cost for the society. The field of transplantation lacks a robust assessment of risk stratification. Thus, it impairs the development of relevant clinical trials to address graft and patient outcomes. We formed the EU-TRAIN project by gathering reference kidney transplant centres in a fully operating European network including 12 partners. Our ambitious but realistic goals are: to provide clinicians with innovative and accessible tools for early prediction of individual risk of allograft rejection and transplant loss; to personalise clinical management and treatment and; to improve allograft outcomes. This project will engineer a risk stratification system applied to kidney transplant patients by analysing the integration of several layers of data (clinical, histological, immunological data as well as gene expression and novel biomarkers) - the TRAnsplant Comprehensive Evaluator of Risk (EU-TRACER). EU-TRACER will be generated and validated in 2 dedicated studies including a randomised control trial. Translation to patients will be achieved by delivering: 1) A multiplex non-invasive biomarker system for the stratification and immune monitoring of low and high risk kidney recipients; 2) A prognostic system for individual risk stratification for allograft rejection and failure that will assist decision making via an interactive web interface. The EU-TRACER, developed with our 3 industrial partners, will define a new standard of care in transplantation. The EU-TRACER will have the potential for a large implementation and diffusion in other centres in Europe and will be suitable for industrial collaboration.